Syncom Formulations (India) Limited (SYNCOMF.BO)
INR 16.66
(3.29%)
INR 16.66
(3.29%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 942.39 Million INR | -8.14% |
| 2022 | 726.37 Million INR | 2.34% |
| 2021 | 709.74 Million INR | -1.76% |
| 2020 | 722.43 Million INR | 68.69% |
| 2019 | 428.26 Million INR | 4.76% |
| 2018 | 408.78 Million INR | 1.24% |
| 2017 | 403.78 Million INR | -14.18% |
| 2016 | 470.5 Million INR | -1.61% |
| 2015 | 478.21 Million INR | -10.22% |
| 2014 | 532.67 Million INR | 7.46% |
| 2013 | 495.71 Million INR | 41.69% |
| 2012 | 349.85 Million INR | 92.95% |
| 2011 | 181.31 Million INR | -69.77% |
| 2010 | 599.72 Million INR | 550.78% |
| 2009 | 92.15 Million INR | 37.06% |
| 2008 | 67.23 Million INR | -0.35% |
| 2007 | 67.47 Million INR | 39.37% |
| 2006 | 48.41 Million INR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 217.92 Million INR | -0.42% |
| 2023 Q4 | 218.85 Million INR | -14.55% |
| 2023 Q3 | 256.1 Million INR | 3.54% |
| 2023 Q2 | 247.34 Million INR | 1.85% |
| 2023 Q1 | 242.86 Million INR | 77.4% |
| 2023 FY | 667.26 Million INR | -8.14% |
| 2022 Q1 | 181.76 Million INR | 39.95% |
| 2022 FY | 726.37 Million INR | 2.34% |
| 2022 Q4 | 136.9 Million INR | -39.45% |
| 2022 Q3 | 226.1 Million INR | 24.5% |
| 2022 Q2 | 181.61 Million INR | -0.08% |
| 2021 Q4 | 129.87 Million INR | -32.31% |
| 2021 Q2 | 205.63 Million INR | 12.77% |
| 2021 Q3 | 191.87 Million INR | -6.69% |
| 2021 FY | 709.74 Million INR | -1.76% |
| 2021 Q1 | 182.35 Million INR | 23.03% |
| 2020 Q3 | 254.82 Million INR | 20.36% |
| 2020 Q4 | 148.21 Million INR | -41.84% |
| 2020 FY | 722.43 Million INR | 68.69% |
| 2020 Q1 | 107.68 Million INR | 749.84% |
| 2020 Q2 | 211.7 Million INR | 96.6% |
| 2019 Q4 | -16.57 Million INR | -111.9% |
| 2019 Q1 | 139.62 Million INR | 493.8% |
| 2019 Q2 | 165.91 Million INR | 18.84% |
| 2019 Q3 | 139.29 Million INR | -16.04% |
| 2019 FY | 428.26 Million INR | 4.76% |
| 2018 Q1 | 99.97 Million INR | -11.01% |
| 2018 FY | 408.78 Million INR | 1.24% |
| 2018 Q4 | 23.51 Million INR | -83.07% |
| 2018 Q3 | 138.88 Million INR | -5.16% |
| 2018 Q2 | 146.44 Million INR | 46.48% |
| 2017 Q2 | 128 Million INR | 3.86% |
| 2017 FY | 403.78 Million INR | -14.18% |
| 2017 Q4 | 112.33 Million INR | -15.68% |
| 2017 Q3 | 133.22 Million INR | 4.08% |
| 2017 Q1 | 123.25 Million INR | -20.25% |
| 2016 Q1 | 135.76 Million INR | 61.35% |
| 2016 FY | 470.5 Million INR | -1.61% |
| 2016 Q4 | 154.54 Million INR | 0.0% |
| 2015 Q3 | 124.92 Million INR | -13.4% |
| 2015 Q1 | 124.89 Million INR | -18.58% |
| 2015 Q2 | 144.25 Million INR | 15.5% |
| 2015 FY | 478.21 Million INR | -10.22% |
| 2015 Q4 | 84.14 Million INR | -32.65% |
| 2014 Q3 | 155.76 Million INR | 1.52% |
| 2014 Q1 | 111.41 Million INR | 15.44% |
| 2014 Q2 | 153.43 Million INR | 37.71% |
| 2014 FY | 532.67 Million INR | 7.46% |
| 2014 Q4 | 153.39 Million INR | -1.52% |
| 2013 Q2 | 130.54 Million INR | 22.78% |
| 2013 Q4 | 96.51 Million INR | -25.44% |
| 2013 FY | 495.71 Million INR | 41.69% |
| 2013 Q1 | 106.32 Million INR | -54.05% |
| 2013 Q3 | 129.45 Million INR | -0.84% |
| 2012 Q4 | 231.38 Million INR | 133.19% |
| 2012 Q2 | 104.62 Million INR | 91.73% |
| 2012 Q3 | 99.22 Million INR | -5.16% |
| 2012 Q1 | 54.56 Million INR | 0.0% |
| 2012 FY | 349.85 Million INR | 92.95% |
| 2011 FY | 181.31 Million INR | -69.77% |
| 2010 FY | 599.72 Million INR | 550.78% |
| 2009 FY | 92.15 Million INR | 37.06% |
| 2008 FY | 67.23 Million INR | -0.35% |
| 2007 FY | 67.47 Million INR | 39.37% |
| 2006 FY | 48.41 Million INR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 26.78 Billion INR | 96.481% |
| Aurobindo Pharma Limited | 154.68 Billion INR | 99.391% |
| Glenmark Life Sciences Limited | 12.43 Billion INR | 92.42% |
| Granules India Limited | 16.79 Billion INR | 94.39% |
| Indoco Remedies Limited | 6.04 Billion INR | 84.401% |
| Achyut Healthcare Limited | 4.86 Million INR | -19286.937% |
| Ajanta Pharma Limited | 21.06 Billion INR | 95.526% |
| Alkem Laboratories Limited | 52.29 Billion INR | 98.198% |
| Alpa Laboratories Limited | 188.89 Million INR | -398.901% |
| Brooks Laboratories Limited | 65.62 Million INR | -1336.146% |
| AstraZeneca Pharma India Limited | 6.22 Billion INR | 84.855% |
| Bajaj HealthCare Limited | 1.47 Billion INR | 35.97% |
| Bliss GVS Pharma Limited | 3.69 Billion INR | 74.498% |
| Dr. Reddy's Laboratories Limited | 163.6 Billion INR | 99.424% |
| Eris Lifesciences Limited | 10.42 Billion INR | 90.962% |
| FDC Limited | 8.33 Billion INR | 88.693% |
| Glenmark Pharmaceuticals Limited | 69.34 Billion INR | 98.641% |
| Gufic Biosciences Limited | 4.16 Billion INR | 77.388% |
| Ind-Swift Laboratories Limited | 6.19 Billion INR | 84.786% |
| Ipca Laboratories Limited | 29.8 Billion INR | 96.839% |
| Jagsonpal Pharmaceuticals Limited | 652.59 Million INR | -44.409% |
| Krebs Biochemicals & Industries Limited | 192.72 Million INR | -388.981% |
| Lasa Supergenerics Limited | 121.02 Million INR | -678.649% |
| Laurus Labs Limited | 24.62 Billion INR | 96.172% |
| Lupin Limited | 123.71 Billion INR | 99.238% |
| Mankind Pharma Limited | 44.52 Billion INR | 97.883% |
| Medicamen Biotech Limited | 495.49 Million INR | -90.193% |
| Medico Remedies Limited | 262.14 Million INR | -259.497% |
| Megasoft Limited | 342.07 Million INR | -175.498% |
| NATCO Pharma Limited | 25.73 Billion INR | 96.338% |
| Piramal Pharma Limited | 24.47 Billion INR | 96.149% |
| RPG Life Sciences Limited | 2.48 Billion INR | 62.046% |
| Sigachi Industries Limited | 2 Billion INR | 52.934% |
| Sun Pharmaceutical Industries Limited | 258.48 Billion INR | 99.635% |
| Suven Pharmaceuticals Limited | 4.12 Billion INR | 77.144% |
| Unichem Laboratories Limited | 4.86 Billion INR | 80.629% |
| Wanbury Limited | 1.73 Billion INR | 45.546% |
| Windlas Biotech Limited | 1.33 Billion INR | 29.609% |
| ZIM Laboratories Limited | 1.26 Billion INR | 25.613% |
| Zydus Lifesciences Limited | 125.21 Billion INR | 99.247% |
| Sun Pharma Advanced Research Company Limited | -602.4 Million INR | 256.439% |
| Divi's Laboratories Limited | 32.44 Billion INR | 97.095% |
| Hester Biosciences Limited | 1.27 Billion INR | 26.008% |
| Procter & Gamble Health Limited | 5.78 Billion INR | 83.699% |
| Amrutanjan Health Care Limited | 1.55 Billion INR | 39.455% |
| Bal Pharma Limited | 770.19 Million INR | -22.358% |
| Strides Pharma Science Limited | 14.38 Billion INR | 93.45% |
| Venus Remedies Limited | 2.18 Billion INR | 56.822% |
| Aarti Pharmalabs Limited | 5.83 Billion INR | 83.839% |
| Nectar Lifesciences Limited | 2.97 Billion INR | 68.291% |
| Shilpa Medicare Limited | 3.54 Billion INR | 73.43% |
| Aarti Drugs Limited | 8.31 Billion INR | 88.668% |
| IOL Chemicals and Pharmaceuticals Limited | 4.58 Billion INR | 79.427% |
| Suven Life Sciences Limited | -200.79 Million INR | 569.329% |
| Ind-Swift Limited | 2.17 Billion INR | 56.622% |
| Valiant Laboratories Limited | -60.66 Million INR | 1653.473% |
| J. B. Chemicals & Pharmaceuticals Limited | 22.69 Billion INR | 95.848% |
| Solara Active Pharma Sciences Limited | 861.2 Million INR | -9.429% |
| Themis Medicare Limited | 1.5 Billion INR | 37.336% |
| Hikal Limited | 3.14 Billion INR | 70.017% |
| Torrent Pharmaceuticals Limited | 46.75 Billion INR | 97.984% |
| Sequent Scientific Limited | 2.97 Billion INR | 68.362% |
| Novartis India Limited | 1.32 Billion INR | 28.977% |
| Wockhardt Limited | 16.24 Billion INR | 94.197% |
| Jubilant Pharmova Limited | 19.64 Billion INR | 95.202% |
| Biofil Chemicals and Pharmaceuticals Limited | 14.57 Million INR | -6363.775% |
| Neuland Laboratories Limited | 8.24 Billion INR | 88.574% |
| Morepen Laboratories Limited | 6.16 Billion INR | 84.704% |
| Kilitch Drugs (India) Limited | 620.47 Million INR | -51.883% |
| Mangalam Drugs & Organics Limited | 703.6 Million INR | -33.939% |